By Fineline Cube 
On August 8, 2025, Hangzhou Tigermed Consulting (SHE: 300347, HKG: 3347), a China-based contract research organization (CRO), and Africare BioPharma officially signed a memorandum of understanding (MOU) to establish a comprehensive partnership. The collaboration aims to enhance clinical research services across Africa by building full-chain capabilities, developing digital research platforms, and fostering talent.
Collaboration Details
The partnership will focus on establishing multi-center clinical research bases with medical and drug regulatory institutes across African countries. These bases will prioritize research in chronic diseases such as diabetes and hyperlipidemia, as well as in cancer and antiviral treatments. By utilizing clinical data from Africa’s diverse population, the initiative aims to accelerate global new drug development.
Digital Innovation and Local Capacity Building
Tigermed will expand its digital services by creating a comprehensive digital clinical research platform. This includes introducing the decentralized/digital clinical trial (DCT) model to Africa, enhancing local clinical research centers, and training talent. The collaboration will also guide the development and refinement of relevant policies and regulations.
Africare BioPharma’s Vision
Africare BioPharma, headquartered in Dar es Salaam, Tanzania, is Africa’s first integrated modern pharmaceutical company focusing on high-end vaccine production, innovative drug R&D, and major disease solutions. Operating under the China-Africa “Belt and Road” framework, Africare aims to reduce Africa’s reliance on imported medicines through localized production and technology transfer. The company seeks to upgrade Africa’s public health system and establish a biopharmaceutical hub serving the continent and beyond.-Fineline Info & Tech